← All Compounds
Mechanism Mimics GLP-1 to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic signaling. Half-Life Approximately 1 week (168 hours) Route subcutaneous Frequency Once weekly
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
Semaglutide
FDA ApprovedGLP-1 Agonist · Novo Nordisk
GLP-1 receptor agonist for type 2 diabetes and chronic weight management. Originally marketed as Ozempic (diabetes) and Wegovy (obesity).
About
Clinical Dosing
0.25-2.4 mgonce weekly
Titration Protocols
Wegovy Label Titration
Source: Wegovy (semaglutide) prescribing information, Novo Nordisk, 2021
| Dose | Duration | Draw (5 mg vial in 2mL) | Notes |
|---|---|---|---|
| 0.25 mg | 4 weeks | 0.10 mL (10 units) | Starting dose |
| 0.5 mg | 4 weeks | 0.20 mL (20 units) | First escalation |
| 1 mg | 4 weeks | 0.40 mL (40 units) | Second escalation |
| 1.7 mg | 4 weeks | 0.68 mL (68 units) | Third escalation |
| 2.4 mg | Maintenance | 0.96 mL (96 units) | Maintenance dose |
Ozempic Label Titration
Source: Ozempic (semaglutide) prescribing information, Novo Nordisk, 2017
| Dose | Duration | Draw (5 mg vial in 2mL) | Notes |
|---|---|---|---|
| 0.25 mg | 4 weeks | 0.10 mL (10 units) | Starting dose |
| 0.5 mg | 4 weeks | 0.20 mL (20 units) | First escalation |
| 1 mg | Maintenance | 0.40 mL (40 units) | Maintenance (may increase to 2 mg) |
Available Vial Sizes
5 mg
5 mg vial
10 mg
10 mg vial